DexCom, Inc. (NASDAQ: DXCM) Stock Competitors & Peer Comparison
See DXCM's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DXCM and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DXCM | $87.90 | -2.02% | 33.2B | 34.47 | $2.55 | N/A |
| ABT | $108.33 | -0.42% | 187.4B | 20.79 | $5.21 | +2.28% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $94.17 | +1.15% | 120.5B | 17.03 | $5.53 | +3.02% |
| SYK | $303.13 | -1.58% | 116.2B | 22.64 | $13.39 | +1.14% |
| BSX | $47.80 | +1.81% | 71.1B | 15.42 | $3.10 | N/A |
| EW | $89.90 | +0.13% | 51.8B | 33.29 | $2.70 | N/A |
| GEHC | $68.86 | -1.23% | 31.1B | 15.10 | $4.56 | +0.20% |
| PHG | $25.89 | -0.61% | 25.3B | 14.79 | $1.75 | +3.82% |
| ZBH | $98.07 | -0.86% | 19B | 11.56 | $8.48 | +0.98% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
DXCM vs ABT Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, ABT has a market cap of 187.4B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while ABT trades at $108.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas ABT's P/E ratio is 20.79. In terms of profitability, DXCM's ROE is +0.36%, compared to ABT's ROE of +0.11%. Regarding short-term risk, DXCM is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
DXCM vs BSX-PA Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, DXCM's ROE is +0.36%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, DXCM is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check BSX-PA's competition here
Medtronic plc (NYSE: MDT)
DXCM vs MDT Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, MDT has a market cap of 120.5B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while MDT trades at $94.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas MDT's P/E ratio is 17.03. In terms of profitability, DXCM's ROE is +0.36%, compared to MDT's ROE of +0.11%. Regarding short-term risk, DXCM is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
DXCM vs SYK Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, SYK has a market cap of 116.2B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while SYK trades at $303.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas SYK's P/E ratio is 22.64. In terms of profitability, DXCM's ROE is +0.36%, compared to SYK's ROE of +0.16%. Regarding short-term risk, DXCM is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
DXCM vs BSX Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, BSX has a market cap of 71.1B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while BSX trades at $47.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas BSX's P/E ratio is 15.42. In terms of profitability, DXCM's ROE is +0.36%, compared to BSX's ROE of +0.15%. Regarding short-term risk, DXCM is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
DXCM vs EW Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, EW has a market cap of 51.8B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while EW trades at $89.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas EW's P/E ratio is 33.29. In terms of profitability, DXCM's ROE is +0.36%, compared to EW's ROE of +0.10%. Regarding short-term risk, DXCM is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check EW's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
DXCM vs GEHC Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, GEHC has a market cap of 31.1B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while GEHC trades at $68.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas GEHC's P/E ratio is 15.10. In terms of profitability, DXCM's ROE is +0.36%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, DXCM is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
DXCM vs PHG Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, PHG has a market cap of 25.3B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while PHG trades at $25.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas PHG's P/E ratio is 14.79. In terms of profitability, DXCM's ROE is +0.36%, compared to PHG's ROE of +0.10%. Regarding short-term risk, DXCM is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
DXCM vs ZBH Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, ZBH has a market cap of 19B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while ZBH trades at $98.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas ZBH's P/E ratio is 11.56. In terms of profitability, DXCM's ROE is +0.36%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, DXCM is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
DXCM vs ABMD Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas ABMD's P/E ratio is 65.36. In terms of profitability, DXCM's ROE is +0.36%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, DXCM is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
DXCM vs PEN Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while PEN trades at $322.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas PEN's P/E ratio is 84.16. In terms of profitability, DXCM's ROE is +0.36%, compared to PEN's ROE of +0.11%. Regarding short-term risk, DXCM is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
DXCM vs SWAV Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas SWAV's P/E ratio is 78.76. In terms of profitability, DXCM's ROE is +0.36%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, DXCM is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
DXCM vs SNN Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, SNN has a market cap of 12.1B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while SNN trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas SNN's P/E ratio is 13.58. In terms of profitability, DXCM's ROE is +0.36%, compared to SNN's ROE of +0.12%. Regarding short-term risk, DXCM is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
DXCM vs ALGN Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, ALGN has a market cap of 11.4B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while ALGN trades at $158.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas ALGN's P/E ratio is 14.46. In terms of profitability, DXCM's ROE is +0.36%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, DXCM is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
DXCM vs GMED Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, GMED has a market cap of 10.6B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while GMED trades at $78.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas GMED's P/E ratio is 17.63. In terms of profitability, DXCM's ROE is +0.36%, compared to GMED's ROE of +0.12%. Regarding short-term risk, DXCM is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
DXCM vs GKOS Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, GKOS has a market cap of 10.5B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while GKOS trades at $177.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas GKOS's P/E ratio is -206.37. In terms of profitability, DXCM's ROE is +0.36%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, DXCM is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check GKOS's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
DXCM vs BIO-B Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, BIO-B has a market cap of 10.4B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while BIO-B trades at $381.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas BIO-B's P/E ratio is -67.15. In terms of profitability, DXCM's ROE is +0.36%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, DXCM is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
DXCM vs BIO Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, BIO has a market cap of 10.4B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while BIO trades at $386.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas BIO's P/E ratio is 41.65. In terms of profitability, DXCM's ROE is +0.36%, compared to BIO's ROE of +0.03%. Regarding short-term risk, DXCM is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check BIO's competition here
Insulet Corp. (NASDAQ: PODD)
DXCM vs PODD Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, PODD has a market cap of 10.2B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while PODD trades at $147.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas PODD's P/E ratio is 25.12. In terms of profitability, DXCM's ROE is +0.36%, compared to PODD's ROE of +0.27%. Regarding short-term risk, DXCM is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check PODD's competition here
Masimo Corporation (NASDAQ: MASI)
DXCM vs MASI Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas MASI's P/E ratio is 44.43. In terms of profitability, DXCM's ROE is +0.36%, compared to MASI's ROE of +0.09%. Regarding short-term risk, DXCM is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
DXCM vs BRKR Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, BRKR has a market cap of 8.9B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while BRKR trades at $58.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas BRKR's P/E ratio is 29.40. In terms of profitability, DXCM's ROE is +0.36%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, DXCM is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
DXCM vs BRKRP Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, BRKRP has a market cap of 8.6B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while BRKRP trades at $431.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas BRKRP's P/E ratio is 234.13. In terms of profitability, DXCM's ROE is +0.36%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, DXCM is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check BRKRP's competition here
Inari Medical, Inc. (NASDAQ: NARI)
DXCM vs NARI Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas NARI's P/E ratio is -59.24. In terms of profitability, DXCM's ROE is +0.36%, compared to NARI's ROE of -0.00%. Regarding short-term risk, DXCM is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check NARI's competition here
Haemonetics Corporation (NYSE: HAE)
DXCM vs HAE Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, HAE has a market cap of 4.7B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while HAE trades at $102.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas HAE's P/E ratio is 20.54. In terms of profitability, DXCM's ROE is +0.36%, compared to HAE's ROE of +0.11%. Regarding short-term risk, DXCM is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check HAE's competition here
LivaNova PLC (NASDAQ: LIVN)
DXCM vs LIVN Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, LIVN has a market cap of 4.5B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while LIVN trades at $81.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas LIVN's P/E ratio is 19.46. In terms of profitability, DXCM's ROE is +0.36%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, DXCM is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
DXCM vs ITGR Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while ITGR trades at $126.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas ITGR's P/E ratio is 19.76. In terms of profitability, DXCM's ROE is +0.36%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, DXCM is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
DXCM vs IRTC Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while IRTC trades at $123.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas IRTC's P/E ratio is -287.05. In terms of profitability, DXCM's ROE is +0.36%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, DXCM is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
DXCM vs AXNX Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas AXNX's P/E ratio is -709.80. In terms of profitability, DXCM's ROE is +0.36%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, DXCM is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
DXCM vs TMDX Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while TMDX trades at $89.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas TMDX's P/E ratio is 45.68. In terms of profitability, DXCM's ROE is +0.36%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, DXCM is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
DXCM vs AXGN Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, AXGN has a market cap of 2.6B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while AXGN trades at $48.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas AXGN's P/E ratio is 127.05. In terms of profitability, DXCM's ROE is +0.36%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, DXCM is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check AXGN's competition here
Neogen Corporation (NASDAQ: NEOG)
DXCM vs NEOG Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while NEOG trades at $11.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas NEOG's P/E ratio is 42.25. In terms of profitability, DXCM's ROE is +0.36%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, DXCM is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check NEOG's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
DXCM vs UFPT Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, UFPT has a market cap of 2.2B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while UFPT trades at $288.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas UFPT's P/E ratio is 29.50. In terms of profitability, DXCM's ROE is +0.36%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, DXCM is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
DXCM vs ESTA Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while ESTA trades at $74.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas ESTA's P/E ratio is -58.96. In terms of profitability, DXCM's ROE is +0.36%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, DXCM is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
DXCM vs NVCR Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while NVCR trades at $17.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas NVCR's P/E ratio is -13.80. In terms of profitability, DXCM's ROE is +0.36%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, DXCM is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check NVCR's competition here
NuVasive, Inc. (NASDAQ: NUVA)
DXCM vs NUVA Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas NUVA's P/E ratio is 75.00. In terms of profitability, DXCM's ROE is +0.36%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, DXCM is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check NUVA's competition here
Butterfly Network, Inc. (NYSE: BFLY)
DXCM vs BFLY Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, BFLY has a market cap of 2B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while BFLY trades at $7.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas BFLY's P/E ratio is -30.67. In terms of profitability, DXCM's ROE is +0.36%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, DXCM is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check BFLY's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
DXCM vs INSP Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while INSP trades at $63.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas INSP's P/E ratio is 27.76. In terms of profitability, DXCM's ROE is +0.36%, compared to INSP's ROE of +0.18%. Regarding short-term risk, DXCM is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check INSP's competition here
CONMED Corporation (NYSE: CNMD)
DXCM vs CNMD Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while CNMD trades at $49.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas CNMD's P/E ratio is 10.84. In terms of profitability, DXCM's ROE is +0.36%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, DXCM is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check CNMD's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
DXCM vs ATEC Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while ATEC trades at $9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas ATEC's P/E ratio is -157.50. In terms of profitability, DXCM's ROE is +0.36%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, DXCM is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check ATEC's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
DXCM vs TNDM Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, TNDM has a market cap of 1.4B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while TNDM trades at $19.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas TNDM's P/E ratio is -21.40. In terms of profitability, DXCM's ROE is +0.36%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, DXCM is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check TNDM's competition here
Heska Corporation (NASDAQ: HSKA)
DXCM vs HSKA Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas HSKA's P/E ratio is -62.49. In terms of profitability, DXCM's ROE is +0.36%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, DXCM is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
DXCM vs IART Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while IART trades at $16.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas IART's P/E ratio is 7.08. In terms of profitability, DXCM's ROE is +0.36%, compared to IART's ROE of -0.01%. Regarding short-term risk, DXCM is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check IART's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
DXCM vs PRCT Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, PRCT has a market cap of 1.3B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while PRCT trades at $22.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas PRCT's P/E ratio is -11.73. In terms of profitability, DXCM's ROE is +0.36%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, DXCM is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check PRCT's competition here
Artivion, Inc. (NYSE: AORT)
DXCM vs AORT Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while AORT trades at $25.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas AORT's P/E ratio is 42.63. In terms of profitability, DXCM's ROE is +0.36%, compared to AORT's ROE of -0.01%. Regarding short-term risk, DXCM is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check AORT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
DXCM vs AVNS Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas AVNS's P/E ratio is 27.77. In terms of profitability, DXCM's ROE is +0.36%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, DXCM is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check AVNS's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
DXCM vs LMRI Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, LMRI has a market cap of 1.2B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while LMRI trades at $12.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas LMRI's P/E ratio is -23.70. In terms of profitability, DXCM's ROE is +0.36%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, DXCM is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
DXCM vs SILK Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas SILK's P/E ratio is -18.96. In terms of profitability, DXCM's ROE is +0.36%, compared to SILK's ROE of -0.35%. Regarding short-term risk, DXCM is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
DXCM vs IRMD Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while IRMD trades at $83.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas IRMD's P/E ratio is 43.51. In terms of profitability, DXCM's ROE is +0.36%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, DXCM is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
DXCM vs FNA Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas FNA's P/E ratio is -19.83. In terms of profitability, DXCM's ROE is +0.36%, compared to FNA's ROE of -0.35%. Regarding short-term risk, DXCM is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check FNA's competition here
Enovis Corporation (NYSE: ENOV)
DXCM vs ENOV Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while ENOV trades at $18.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas ENOV's P/E ratio is 5.31. In terms of profitability, DXCM's ROE is +0.36%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, DXCM is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check ENOV's competition here
Bioventus Inc. (NASDAQ: BVS)
DXCM vs BVS Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, BVS has a market cap of 953.2M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while BVS trades at $14.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas BVS's P/E ratio is 18.51. In terms of profitability, DXCM's ROE is +0.36%, compared to BVS's ROE of +0.28%. Regarding short-term risk, DXCM is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
DXCM vs CBLL Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, CBLL has a market cap of 937.9M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while CBLL trades at $24.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas CBLL's P/E ratio is -14.05. In terms of profitability, DXCM's ROE is +0.36%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, DXCM is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check CBLL's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
DXCM vs AHCO Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, AHCO has a market cap of 883M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while AHCO trades at $6.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas AHCO's P/E ratio is 13.24. In terms of profitability, DXCM's ROE is +0.36%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, DXCM is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check AHCO's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
DXCM vs AVR Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, AVR has a market cap of 879M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while AVR trades at $9.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas AVR's P/E ratio is -4.66. In terms of profitability, DXCM's ROE is +0.36%, compared to AVR's ROE of -0.78%. Regarding short-term risk, DXCM is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check AVR's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
DXCM vs BBNX Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, BBNX has a market cap of 873.7M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while BBNX trades at $19.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas BBNX's P/E ratio is -11.77. In terms of profitability, DXCM's ROE is +0.36%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, DXCM is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check BBNX's competition here
InMode Ltd. (NASDAQ: INMD)
DXCM vs INMD Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, INMD has a market cap of 857M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while INMD trades at $14.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas INMD's P/E ratio is 10.35. In terms of profitability, DXCM's ROE is +0.36%, compared to INMD's ROE of +0.12%. Regarding short-term risk, DXCM is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check INMD's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
DXCM vs CSII Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas CSII's P/E ratio is -20.83. In terms of profitability, DXCM's ROE is +0.36%, compared to CSII's ROE of -0.14%. Regarding short-term risk, DXCM is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
DXCM vs SIBN Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, SIBN has a market cap of 820.5M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while SIBN trades at $18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas SIBN's P/E ratio is -54.41. In terms of profitability, DXCM's ROE is +0.36%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, DXCM is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check SIBN's competition here
Varex Imaging Corporation (NASDAQ: VREX)
DXCM vs VREX Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, VREX has a market cap of 779.3M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while VREX trades at $18.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas VREX's P/E ratio is 19.48. In terms of profitability, DXCM's ROE is +0.36%, compared to VREX's ROE of +0.05%. Regarding short-term risk, DXCM is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check VREX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
DXCM vs SSII Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, SSII has a market cap of 682.4M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while SSII trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas SSII's P/E ratio is -66.51. In terms of profitability, DXCM's ROE is +0.36%, compared to SSII's ROE of -0.27%. Regarding short-term risk, DXCM is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check SSII's competition here
Surmodics, Inc. (NASDAQ: SRDX)
DXCM vs SRDX Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas SRDX's P/E ratio is -34.66. In terms of profitability, DXCM's ROE is +0.36%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, DXCM is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
DXCM vs CTKB Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, CTKB has a market cap of 607M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while CTKB trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas CTKB's P/E ratio is -24.90. In terms of profitability, DXCM's ROE is +0.36%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, DXCM is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check CTKB's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
DXCM vs APEN Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas APEN's P/E ratio is -9.43. In terms of profitability, DXCM's ROE is +0.36%, compared to APEN's ROE of -0.85%. Regarding short-term risk, DXCM is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check APEN's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
DXCM vs KIDS Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, KIDS has a market cap of 575.6M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while KIDS trades at $22.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas KIDS's P/E ratio is -18.99. In terms of profitability, DXCM's ROE is +0.36%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, DXCM is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check KIDS's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
DXCM vs DCTH Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, DCTH has a market cap of 568.9M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while DCTH trades at $16.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas DCTH's P/E ratio is 1648.00. In terms of profitability, DXCM's ROE is +0.36%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, DXCM is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
DXCM vs ZIMV Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, DXCM's ROE is +0.36%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, DXCM is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
DXCM vs CERS Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, CERS has a market cap of 521.9M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while CERS trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas CERS's P/E ratio is -51.70. In terms of profitability, DXCM's ROE is +0.36%, compared to CERS's ROE of -0.10%. Regarding short-term risk, DXCM is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
DXCM vs NPCE Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, NPCE has a market cap of 508M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while NPCE trades at $14.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas NPCE's P/E ratio is -26.14. In terms of profitability, DXCM's ROE is +0.36%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, DXCM is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check NPCE's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
DXCM vs TCMD Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, TCMD has a market cap of 493.3M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while TCMD trades at $21.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas TCMD's P/E ratio is 20.25. In terms of profitability, DXCM's ROE is +0.36%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, DXCM is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check TCMD's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
DXCM vs SGHT Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, SGHT has a market cap of 454.3M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while SGHT trades at $8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas SGHT's P/E ratio is -14.91. In terms of profitability, DXCM's ROE is +0.36%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, DXCM is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check SGHT's competition here
Carlsmed, Inc. (NASDAQ: CARL)
DXCM vs CARL Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, CARL has a market cap of 424.1M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while CARL trades at $15.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas CARL's P/E ratio is -10.91. In terms of profitability, DXCM's ROE is +0.36%, compared to CARL's ROE of -0.38%. Regarding short-term risk, DXCM is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check CARL's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
DXCM vs PACB Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, PACB has a market cap of 419.3M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while PACB trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas PACB's P/E ratio is -3.29. In terms of profitability, DXCM's ROE is +0.36%, compared to PACB's ROE of -49.62%. Regarding short-term risk, DXCM is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check PACB's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
DXCM vs CLPT Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, CLPT has a market cap of 418.7M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while CLPT trades at $13.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas CLPT's P/E ratio is -11.83. In terms of profitability, DXCM's ROE is +0.36%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, DXCM is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check CLPT's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
DXCM vs SENS Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, SENS has a market cap of 402.5M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while SENS trades at $9.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas SENS's P/E ratio is -4.32. In terms of profitability, DXCM's ROE is +0.36%, compared to SENS's ROE of -1.66%. Regarding short-term risk, DXCM is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
DXCM vs OFIX Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, OFIX has a market cap of 375.5M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while OFIX trades at $9.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas OFIX's P/E ratio is -6.05. In terms of profitability, DXCM's ROE is +0.36%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, DXCM is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check OFIX's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
DXCM vs CATX Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, CATX has a market cap of 358.1M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while CATX trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas CATX's P/E ratio is -2.36. In terms of profitability, DXCM's ROE is +0.36%, compared to CATX's ROE of -0.42%. Regarding short-term risk, DXCM is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check CATX's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
DXCM vs TMCI Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, TMCI has a market cap of 312M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while TMCI trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas TMCI's P/E ratio is -5.12. In terms of profitability, DXCM's ROE is +0.36%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, DXCM is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check TMCI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
DXCM vs SMLR Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas SMLR's P/E ratio is 3.92. In terms of profitability, DXCM's ROE is +0.36%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, DXCM is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check SMLR's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
DXCM vs TLSI Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, TLSI has a market cap of 307.9M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while TLSI trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas TLSI's P/E ratio is -2.98. In terms of profitability, DXCM's ROE is +0.36%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, DXCM is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check TLSI's competition here
CapsoVision, Inc. (NASDAQ: CV)
DXCM vs CV Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, CV has a market cap of 299.3M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while CV trades at $5.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas CV's P/E ratio is -2.40. In terms of profitability, DXCM's ROE is +0.36%, compared to CV's ROE of -1.78%. Regarding short-term risk, DXCM is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check CV's competition here
Avita Medical Inc. (NASDAQ: RCEL)
DXCM vs RCEL Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, RCEL has a market cap of 278.2M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while RCEL trades at $11.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas RCEL's P/E ratio is -7.78. In terms of profitability, DXCM's ROE is +0.36%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, DXCM is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check RCEL's competition here
RxSight, Inc. (NASDAQ: RXST)
DXCM vs RXST Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, RXST has a market cap of 263.9M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while RXST trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas RXST's P/E ratio is -5.64. In terms of profitability, DXCM's ROE is +0.36%, compared to RXST's ROE of -0.17%. Regarding short-term risk, DXCM is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check RXST's competition here
Profound Medical Corp. (NASDAQ: PROF)
DXCM vs PROF Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, PROF has a market cap of 250.4M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while PROF trades at $6.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas PROF's P/E ratio is -7.03. In terms of profitability, DXCM's ROE is +0.36%, compared to PROF's ROE of -0.56%. Regarding short-term risk, DXCM is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check PROF's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
DXCM vs INFU Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, INFU has a market cap of 246M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while INFU trades at $12.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas INFU's P/E ratio is 29.73. In terms of profitability, DXCM's ROE is +0.36%, compared to INFU's ROE of +0.15%. Regarding short-term risk, DXCM is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
DXCM vs MGRM Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas MGRM's P/E ratio is -12.00. In terms of profitability, DXCM's ROE is +0.36%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, DXCM is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
DXCM vs ELMD Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, ELMD has a market cap of 232.1M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while ELMD trades at $28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas ELMD's P/E ratio is 21.40. In terms of profitability, DXCM's ROE is +0.36%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, DXCM is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
DXCM vs NVRO Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas NVRO's P/E ratio is -1.91. In terms of profitability, DXCM's ROE is +0.36%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, DXCM is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
DXCM vs STIM Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, STIM has a market cap of 200.4M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while STIM trades at $2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas STIM's P/E ratio is -6.55. In terms of profitability, DXCM's ROE is +0.36%, compared to STIM's ROE of -1.51%. Regarding short-term risk, DXCM is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check STIM's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
DXCM vs BSGM Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas BSGM's P/E ratio is -5.81. In terms of profitability, DXCM's ROE is +0.36%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, DXCM is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
DXCM vs LUCD Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, LUCD has a market cap of 179.2M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while LUCD trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas LUCD's P/E ratio is -2.54. In terms of profitability, DXCM's ROE is +0.36%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, DXCM is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
DXCM vs MDGS Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas MDGS's P/E ratio is -0.27. In terms of profitability, DXCM's ROE is +0.36%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, DXCM is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
DXCM vs QIPT Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas QIPT's P/E ratio is -15.87. In terms of profitability, DXCM's ROE is +0.36%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, DXCM is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
DXCM vs FOCL Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, FOCL has a market cap of 155.6M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while FOCL trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas FOCL's P/E ratio is -4.01. In terms of profitability, DXCM's ROE is +0.36%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, DXCM is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check FOCL's competition here
Quantum-Si incorporated (NASDAQ: QSI)
DXCM vs QSI Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, QSI has a market cap of 151.5M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while QSI trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas QSI's P/E ratio is -1.67. In terms of profitability, DXCM's ROE is +0.36%, compared to QSI's ROE of -0.47%. Regarding short-term risk, DXCM is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check QSI's competition here
Inogen, Inc. (NASDAQ: INGN)
DXCM vs INGN Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, INGN has a market cap of 146.7M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while INGN trades at $5.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas INGN's P/E ratio is -5.96. In terms of profitability, DXCM's ROE is +0.36%, compared to INGN's ROE of -0.13%. Regarding short-term risk, DXCM is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
DXCM vs QTRX Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, QTRX has a market cap of 126.7M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while QTRX trades at $2.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas QTRX's P/E ratio is -1.06. In terms of profitability, DXCM's ROE is +0.36%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, DXCM is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check QTRX's competition here
iCAD, Inc. (NASDAQ: ICAD)
DXCM vs ICAD Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas ICAD's P/E ratio is -20.37. In terms of profitability, DXCM's ROE is +0.36%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, DXCM is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for DXCM.Check ICAD's competition here
LENSAR Inc (NASDAQ: LNSR)
DXCM vs LNSR Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, LNSR has a market cap of 105.4M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while LNSR trades at $8.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas LNSR's P/E ratio is 8.76. In terms of profitability, DXCM's ROE is +0.36%, compared to LNSR's ROE of +103.80%. Regarding short-term risk, DXCM is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check LNSR's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
DXCM vs HJLI Comparison September 2026
DexCom, Inc. (NASDAQ: DXCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 33.2B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, DXCM is priced at $87.90 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 34.47, whereas HJLI's P/E ratio is N/A. In terms of profitability, DXCM's ROE is +0.36%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, DXCM is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for DXCM.Check HJLI's competition here